Sun Pharmaceutical Industries enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


4,21,677	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
30,704	30,704	23,925	17,870	13,996
310	310	268	3,439	3,320
4,082	4,082	1,870	2,846	6,198
3,95,364	—	—	—	—
−26,622	−26,622	−22,055	−15,025	−7,798
₹1,647.83	—	—	—	—

87,961	87,961	74,356	69,952	65,513
4.6%	4.6%	2.5%	4.1%	9.5%
0.01×	—	—	—	—

6.60×	—	—	—	—
22.15×	—	—	—	—
26.59×	—	—	—	—
44.88×	—	—	—	—
59,911	58,462	52,578	48,497	43,886
17,847	17,731	15,272	13,023	11,647
14,871	14,794	12,696	10,466	9,117
—	12,419	14,072	12,135	4,959
8,810	8,810	11,944	9,933	2,874
—	8,732	11,898	9,905	2,865
—	3,609	2,129	2,202	2,086

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUNPHARMA₹1,757.50

Sun Pharmaceutical Industries Ltd.

· Pharma & Health

₹ CrorePeersCIPLA DRREDDY LUPIN APOLLOHOSP MAXHEALTH DIVISLAB TORNTPHARM ZYDUSLIFEMcap ₹4.22L Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	4,21,677.0
- Cash, Equiv & ST Investments	13,996.3	17,870.2	23,924.9	30,704.0	30,704.0
+ Minority Interest	3,320.1	3,439.2	267.9	309.7	309.7
+ Total Debt	6,197.9	2,845.7	1,869.6	4,081.6	4,081.6
Enterprise Value	—	—	—	—	3,95,364.3
Net Debt (memo)	-7,798.5	-15,024.5	-22,055.2	-26,622.4	-26,622.4
EV per Share	—	—	—	—	1,647.83

Total Capital	65,513.4	69,951.7	74,355.6	87,961.4	87,961.4
Total Debt/Total Capital	9.46	4.07	2.51	4.64	4.64
Total Debt/EV	—	—	—	—	0.01

EV/Sales	—	—	—	—	6.60
EV/EBITDA	—	—	—	—	22.15
EV/EBIT	—	—	—	—	26.59
EV/Free Cash Flow	—	—	—	—	44.88
Reference Items — Trailing FY Values
Sales	43,885.7	48,496.9	52,578.4	58,462.0	59,910.5
EBITDA	11,646.8	13,023.1	15,271.7	17,731.4	17,847.4
EBIT	9,117.4	10,466.5	12,696.3	14,793.6	14,871.4
Operating Cash Flow	4,959.3	12,135.0	14,072.1	12,419.2	—
Free Cash Flow	2,873.8	9,933.2	11,943.5	8,809.8	8,809.8
FCFF (free cash flow to the firm)	2,864.8	9,904.7	11,898.4	8,731.9	—
Capital Expenditure	2,085.6	2,201.8	2,128.6	3,609.4	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 199%.